In vitro and in vivo interaction of moxidectin with BCRP/ABCG2

Chemico-Biological Interactions

Volumn 180, Issue 1, 2009, Pages 106-112

  Perez, Miriam ^a   Blazquez, Alba G ^b   Real, Rebeca ^a   Mendoza, Gracia ^a   Prieto, Julio G ^a   Merino, Gracia ^a   Alvarez, Ana I ^a  

^a UNIVERSITY OF LEÓN   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

BCRP ABCG2; Cellular transport; Efflux; Milk secretion; Moxidectin

Indexed keywords

ACRIDONE DERIVATIVE; BREAST CANCER RESISTANCE PROTEIN; DRUG RESIDUE; MOXIDECTIN; OXYTOCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILE; BREAST MILK; CELL STRAIN; CELL TRANSPORT; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG INTERACTION; DRUG TRANSPORT; EPITHELIUM; FEMALE; GENETIC TRANSFECTION; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; KNOCKOUT MOUSE; LACTATION; MALE; MOLECULAR INTERACTION; MOUSE; NONHUMAN; OOCYTE; POLARIZATION; PROTEIN EXPRESSION; PROTEIN SECRETION; TISSUE DISTRIBUTION; WILD TYPE; XENOPUS LAEVIS;

ANIMALS; ANTHELMINTICS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE; FEMALE; HUMANS; MACROLIDES; MALE; MICE; MICE, KNOCKOUT; MILK; XENOPUS;

MUS; XENOPUS LAEVIS;

EID: 67349092076     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2009.02.009     Document Type: Article

References (44)

1. Szakács G., Váradi A., Ozvegy-Laczka C., and Sarkadi B. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov. Today 13 (2008) 379-393
2. Schinkel A.H., and Jonker J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev. 55 (2003) 3-29
3. Shoop W., and Soll M. Chemistry, pharmacology and safety of the macrocyclic lactones. In: Vercruysse J., and Rew R.S. (Eds). Macrocyclic Lactones in Antiparasitic Therapy (2002), CAB International 1-30
4. Cotreau M.M., Warren S., Ryan J.L., Fleckenstein L., Vanapalli S.R., Brown K.R., Rock D., Chen C.-Y., and Schwertschlag U.S. The antiparasitic moxidectin: safety, tolerability, and pharmacokinetics in humans. J. Clin. Pharmacol. 43 (2003) 1108-1115
5. Laffont C.M., Toutain P.L., Alvinerie M., and Bousquet-Mélou A. Intestinal secretion is the major route for parent ivermectin elimination in the rat. Drug Metab. Dispos. 30 (2002) 626-630
6. Lespine A., Solenne M., Dupuy J., Roulet A., Pineau T., Orlowski S., and Alvinerie M. Interaction of macrocyclic lactones with P-glycoprotein: structure-affinity relationship. Eur. J. Pharm. Sci. 30 (2007) 84-94
7. Brayden D.J., and Griffin J. Avermectin transepithelial transport in MDR1- and MRP-transfected canine kidney monolayers. Vet. Res. Commun. 32 (2008) 93-106
8. Griffin J., Fletcher N., Clemence R., Blanchflower S., and Brayden D.J. Selamectin is a potent substrate and inhibitor of human and canine P-glycoprotein. J. Vet. Pharmacol. Ther. 28 (2005) 257-265
9. Didier A., and Loor F. The abamectin derivative ivermectin is a potent P-glycoprotein inhibitor. Anticancer, Drugs 7 (1996) 745-751
10. Schinkel A.H., Smit J.J., van Tellingen O., Beijnen J.H., Wagenaar E., van Deemter L., Mol C.A., van der Valk M.A., Robanus-Maandag E.C., te Riele H.P.J., Berns A.J.M., and Borst P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77 (1994) 491-502
11. Muenster U., Grieshop B., Ickenroth K., and Gnoth M.J. Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions. Pharm. Res. 25 (2008) 2320-2326
12. Jonker J.W., Merino G., Musters S., van Herwaarden A.E., Bolscher E., Wagenaar E., Mesman E., Dale T.C., and Schinkel A.H. The breast cancer resistance protein (BCRP/ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat. Med. 11 (2005) 127-129
13. Pulido M.M., Molina A.J., Merino G., Prieto J.G., and Alvarez A.I. Interaction of enrofloxacin with breast cancer resistance protein (BCRP/ABCG2): influence of flavonoids and role in milk secretion in sheep. J. Vet. Pharmacol. Ther. 29 (2006) 279-287
14. Jonker J.W., Buitelaar M., Wagenaar E., van der Valk M.A., Scheffer G.L., Scheper R.J., Plösch T., Kuipers F., Elferink R.P., Rosing H., Beijnen J.H., and Schinkel A.H. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 15649-15654
15. Van Herwaarden A.E., Jonker J.W., Wagenaar E., Brinkhuis R.F., Schellens J.H.M., Beijnen J.H., and Schinkel A.H. The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Res. 63 (2003) 6447-6452
16. Van Herwaarden A.E., Wagenaar E., Karnekamp B., Merino G., Jonker J.W., and Schinkel A.H. Breast cancer resistance protein (Bcrp1/Abcg2) reduce systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk. Carcinogenesis 27 (2006) 123-130
17. Agatonovic-Kustrin S., Tucker G., Zecevic M., and Zivanovic L.J. Prediction of drug transfer into human milk based on molecular structure descriptors. Anal. Chim. Acta 418 (2000) 181-195
18. Gerk P.M., Oo C.Y., Paxton E.W., Moscow J.A., and McNamara P.J. Interactions between cimetidine, nitrofurantoin, and probenecid active transport into rat milk. J. Pharmacol. Exp. Ther. 296 (2001) 175-180
19. Imperiale F., Busetti M.R., Suarez V.H., and Lanusse C. Milk excretion of ivermectin and moxidectin in dairy sheep: assessment of drug residues during cheese elaboration and ripening period. J. Agric. Food Chem. 52 (2004) 6205-6211
20. Rabindran S.K., Ross D.D., Doyle L.A., Yang W., and Greenberger L.M. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res. 60 (2000) 47-50
21. Boumendjel A., Macalou S., Ahmed-Belkacem A., Blanc M., and Di Pietro A. Acridone derivatives: design, synthesis, and inhibition of breast cancer resistance protein ABCG2. Bioorg. Med. Chem. 15 (2007) 2892-2897
22. Jonker J.W., Smit J.W., Brinkhuis R.F., Maliepaard M., Beijnen J.H., Schellens J.H.M., and Schinkel A.H. Role of breast cancer resistance protein in the J.H.M bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst. 92 (2000) 1651-1656
23. Merino G., Jonker J.W., Wagenaar E., Pulido M.M., Molina A.J., Alvarez A.I., and Schinkel A.H. Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2). Drug Metab. Dispos. 33 (2005) 614-618
24. Briz O., Serrano M.A., Rebollo N., Hagenbuch B., Meier P.J., Koepsell H., and Marin J.J.G. Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum(II) and cis-diammine-bisursodeoxycholate-platinum(II) toward liver cells. Mol. Pharmacol. 61 (2002) 853-860
25. Ben Aziz R., and Soreq H. Improving poor in vitro transcription from G,C-rich genes. Nucleic Acids Res. 18 (1990) 3418
26. Schrickx J.A., and Fink-Gremmels J. Implications of ABC transporters on the disposition of typical veterinary medicinal products. Eur. J. Pharmacol. 585 (2008) 510-519
27. Molento M.B., Lifschitz A., Sallovitz J., Lanusse C., and Prichard R. Influence of verapamil on the pharmacokinetics of the antiparasitic drugs ivermectin and moxidectin in sheep. Parasitol. Res. 92 (2004) 121-127
28. Dupuy J., Larrieu G., Sutra J.F., Lespine A., and Alvinerie M. Enhancement of moxidectin bioavailability in lamb by a natural flavonoid: quercetin. Vet. Parasitol. 112 (2003) 337-347
29. Paul A.J., Hutchens D.E., Firkins L.D., and Borgstrom M. Dermal safety study with imidacloprid/moxidectin topical solution in the ivermectin-sensitive collie. Vet. Parasitol. 121 (2004) 285-291
30. Mealey K.L. Canine ABCB1 and macrocyclic lactones: heartworm prevention and pharmacogenetics. Vet. Parasitol. 158 (2008) 215-222
31. 14C moxidectin in cultured rat hepatocytes. J. Vet. Pharmacol. Ther. 24 (2001) 171-177
32. Dupuy J., Lespine A., Sutra J.F., and Alvinerie M. The interaction between moxidectin and MDR transporters in primary cultures of rats hepatocytes. J. Vet. Pharmacol. Ther. 29 (2006) 107-111
33. Dupuy J., Lespine A., Sutra J.F., and Alvinerie M. Fumagillin, a new P-glycoprotein-interfering agent able to modulate moxidectin efflux in rat hepatocytes. J. Vet. Pharmacol. Ther. 29 (2006) 489-494
34. Nakanishi T., Doyle L.A., Hassel B., Wei Y., Wu K.S., Bauer S., Pumplin D.W., Fang H.B., and Ross D.D. Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis. Mol. Pharmacol. 64 (2003) 1452-1462
35. Morin X.K., Bond T.D., Loo T.W., Clarke D.M., and Bear C.E. Failure of P-glycoprotein (MDR1) expressed in Xenopus oocytes to produce swelling-activated chloride channel activity. J. Physiol. 486 (1995) 707-714
36. Vallejo M., Briz O., Serrano M.A., Monte M.J., and Marin J.J. Potential role of trans-inhibition of the bile salt export pump by progesterone metabolites in the etiopathogenesis of intrahepatic cholestasis of pregnancy. J. Hepatol. 44 (2006) 1150-1157
37. Janke D., Mehralivand S., Strand D., Gödtel-Armbrust U., Habermeier A., Gradhand U., Fischer C., Toliat M.R., Fritz P., Zanger U.M., Schwab M., Fromm M.F., Nürnberg P., Wojnowski L., Closs E.I., and Lang T. 6-mercaptopurine and 9-(2-phosphonyl-methoxyethyl) adenine (PMEA) transport altered by two missense mutations in the drug transporter gene ABCC4. Hum. Mutat. 29 (2008) 659-669
38. Zhang Y., Wang H., Unadkat J.D., and Mao Q. Breast cancer resistance protein 1 limits fetal distribution of nitrofurantoin in the pregnant mouse. Drug Metab. Dispos. 35 (2007) 2154-2158
39. Zhou L., Naraharisetti S.B., Wang H., Unadkat J.D., Hebert M.F., and Mao Q. The breast cancer resistance protein (Bcrp1/Abcg2) limits fetal distribution of glyburide in the pregnant mouse: an Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study. Mol. Pharmacol. 73 (2008) 949-959
40. Zulalian J., Stout S.J., da Cunha A.R., Garces T., and Miller P. Absorption, tissue distribution, metabolism and excretion of moxidectin in cattle. J. Agric. Food Chem. 42 (1994) 381-387
41. Lifschitz A., Virkel G., Imperiale F., Sutra J.F., Galtier P., Lanusse C., and Alvinerie M. Moxidectin in cattle: correlation between plasma and target tissues disposition. J. Vet. Pharmacol. Ther. 22 (1999) 266-273
42. Tanaka Y., Slitt A.L., Leazer T.M., Maher J.M., and Klaassen C.D. Tissues distribution and hormonal regulation of the breast cancer resistance protein (Bcrp/Abcg2) in rats and mice. Biochem. Biophys. Res. Commun. 326 (2004) 181-187
43. Merino G., van Herwaarden A.E., Wagenaar E., Jonker J.W., and Schinkel A.H. Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver. Mol. Pharmacol. 67 (2005) 1765-1771
44. Yoshikawa M., Ikegami Y., Sano K., Yoshida H., Mitomo H., Sawada S., and Ishikawa T. Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid. J. Exp. Ther. Oncol. 4 (2004) 25-35